Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study
A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate-to-severe UC. NCT04023396.
Authors
- Severine A.R.A. Vermeire (ORCID: https://orcid.org/0000-0001-9942-3019)
- Marla C. Dubinsky (ORCID: https://orcid.org/0000-0003-4968-5795)
- Julien Santo (ORCID: https://orcid.org/0000-0002-3477-8211)
- Parambir S. Dulai (ORCID: https://orcid.org/0000-0002-9514-2321)
- Didier Scherrer (ORCID: https://orcid.org/0000-0001-9835-8550)
- Britta Siegmund (ORCID: https://orcid.org/0000-0002-0055-958X)
- K Shan
- Paul Gineste
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Josianne Nitcheu (ORCID: https://orcid.org/0000-0003-2713-6605)
- Herbert Tilg
- Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
- Christopher J. Rabbat (ORCID: https://orcid.org/0000-0002-1609-6655)
- Aurélien Flatres
- Laurent Peyrin-Biroulet
- Bruce E. Sands
Institutions
- Northwestern University (US)
- Innsbruck Medical University (AT)
- Inserm (FR)
- Universität Innsbruck (AT)
- Humboldt-Universität zu Berlin (DE)
- Mount Sinai Hospital (US)
- IRCCS Ospedale San Raffaele (IT)
- Kyorin University Hospital (JP)
- Abivax (France) (FR)
- Nutrition-Génétique et Exposition aux Risques Environnementaux (FR)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Icahn School of Medicine at Mount Sinai (US)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf074
- Citations
- 9
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 16.36